A Phase 1a/1b, first-in-human, open-label, non-randomised, multicenter, dose-escalation and dose -expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with an anti-PD-1 monoclonal antibody (cemiplimab) in subjects with advanced solid tumours: phase 1a
Latest Information Update: 01 Jul 2025
At a glance
- Drugs AXA 042 (Primary) ; Cemiplimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Axelia Oncology
Most Recent Events
- 01 Jul 2025 New trial record
- 15 Feb 2025 According to Axelia Oncology media release, the company has entered into a clinical supply agreement with Regeneron to explore the combination of Axelia's drug AXA-042 and Regeneron's PD-1 inhibitor Libtayo (cemiplimab) in this trial. This trial will be initiated at 6 clinical trial sites in Australia.